Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
Nurix enrolled the first patient in the Phase 1b/2 NX-5948-203 study combining bexobrutideg, its oral BTK degrader, with venetoclax in relapsed/refractory CLL. The trial runs under the Nurix-Roche global collaboration, with potential expansion to first-line CLL and additional cohorts pairing bexobrutideg with rituximab and obinutuzumab.
Key figures
- Drug Name
- bexobrutideg (NX-5948)
- Phase Of Trial
- Phase 1b/2
- Nct id
- NCT07520006
- Indication
- relapsed/refractory CLL/SLL, potential expansion to first-line CLL
- Study name
- NX-5948-203
- Combination partner
- venetoclax (BCL2 inhibitor)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.